← Search & browse all drugs

fluoroethyl-L-tyrosine (18F)

V09IX10

Forms & Strengths

Sterile aqueous solution for intravenous injection, radiopharmaceutical
Specific activity expressed in megabecquerels (MBq)
Typical vial contains 200–370 MBq at time of calibration

Adult Dosing

Single IV bolus of 200 MBq (range 150–370 MBq) for brain PET imaging
Administered over <30 seconds, followed by saline flush
Imaging starts 20–40 minutes post‑injection

Pediatric Dosing

3.5 MBq/kg IV bolus, not to exceed 200 MBq total activity
Same administration technique as adults
Adjust imaging window to 30–50 minutes after injection

Indications

PET imaging of primary and recurrent brain tumors (gliomas, astrocytomas)
Tumor grading and treatment planning (radiotherapy target delineation)
Differentiation of tumor recurrence from post‑treatment changes

Mechanism of Action

L‑tyrosine analog labeled with 18F, transported via LAT1 amino‑acid transporter
Reflects increased amino‑acid transport and protein synthesis in tumor cells
Low uptake in normal brain yields high tumor‑to‑background contrast

Contraindications

Pregnancy or lactation (radiation exposure to fetus/infant)
Known hypersensitivity to any component of the formulation
Inability to remain motionless for the required imaging period

Adverse Reactions

Generally well tolerated; most common are mild injection‑site discomfort
Transient nausea, flushing, or headache reported in <5% of patients
Rare allergic reactions (e.g., urticaria, anaphylaxis)

Drug Interactions

No clinically significant drug‑drug interactions identified
High protein meals may modestly reduce tumor uptake (competition at LAT1)
Concurrent use of other LAT1 substrates (e.g., certain chemotherapeutics) could theoretically affect uptake

Curated Content: Needs Vetting Before Put to Clinical Use